Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA Gives RMAT Boost To AlloVir As Viralym-M Phase III Planning Continues

Executive Summary

Multi-virus specific T-cell brings the number of known RMAT awards to 29, as detailed in our updated RMAT tracker table. AlloVir's product aims to restore natural T-cell immunity in immunocompromised patients.

Related Content

Keeping Track: US FDA Closes Out First Half Of 2019 With CRL For Edsivo, But A Burst Of Supplemental Approvals
BIO 2019 Notebook: Merck; RMAT; Out-Licensing Deals
ElevateBio Announces AlloVir As First Spoke In Its Cell And Gene Therapy Hub


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts